drugset / Trial / NCT00000826

Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites

NCT00000826

Open-labelTreatment

Summary

To determine the effects of fluconazole and either rifabutin or clarithromycin, alone and in combination, on the pharmacokinetics of first sulfamethoxazole-trimethoprim and then dapsone in HIV-infected patients. Although prophylaxis for more than one opportunistic infection is emerging as a common clinical practice in patients with advanced HIV disease, little is known about possible adverse drug interactions. The need exists to define pharmacokinetics and pharmacodynamic adverse interactions of the many combination prophylactic regimens that may be prescribed.

Timeline

Start
Primary completion
Completion
1999-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 500 mg
Subject Dapsone Small molecule
Subject Fluconazole Small molecule 200 mg
Subject Rifabutin Small molecule 300 mg
Subject trimethoprim-sulfamethoxazole Unknown 160 mg
Subject trimethoprim-sulfamethoxazole Unknown 800 mg